about
Cyclophosphamide-induced symptomatic hyponatremia, a rare but severe side effect: a case report.A Grave Outcome of Posterior Reversible Encephalopathy Syndrome in a Patient Receiving Avastin (Bevacizumab) for Metastatic High-Grade Serous Ovarian Cancer.Severe hypophosphatemia induced after first cycle of the ESHAP protocol for Hodgkin's lymphoma: a case report.Toxic epidermal necrolysis associated with antiepileptic drugs and cranial radiation therapy.A Review of Clinical Outcomes Associated with Two Meropenem Dosing Strategies.Nutrition therapy for critically ill and injured patients.Base deficit and serum lactate concentration in patients with post traumatic convulsion.Point prevalence survey of antimicrobial utilization in oncology patients.Clinical pharmacokinetics: perceptions of hospital pharmacists in Qatar about how it was taught and how it is applied.Law, Culture, and Fear: A Qualitative Study of Health Professionals' Perceptions of Narcotic Use Related to Cancer PainEffect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort studyPerceptions and expectations of health care providers towards clinical pharmacy services at a tertiary cancer centre in QatarPractice implications of an antimicrobial stewardship intervention in a tertiary care teaching hospital, QatarIbrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review
P50
Q34352778-28036D4A-EDBB-4A54-B22A-424DC1E160D1Q36028622-9CB6E91D-B544-4028-9502-B35392225B08Q36882557-D9BCACD4-6D0E-4A9E-99E2-F1EA512D50E9Q37101175-FE92A7EE-DEDE-461B-8C01-76A35E883BAAQ37653459-2E96CACE-3CC0-4358-95A1-BA8B9E250D1FQ38713102-88167C98-A4F6-4204-8276-F6D4C191C682Q39334266-D7F07332-4EF4-4FC2-B118-92569515196FQ44463314-95F04E84-B726-4646-9182-15BC07733FE8Q50564567-E358B922-5566-4F63-93E8-35C70C136527Q89856785-6DE61EA2-A83C-40F1-84CF-8D8B15E6827FQ91148852-48150F3D-4049-45D6-89EE-702503A79447Q91256561-4F7BB766-F53A-4EC0-AE04-4AD18E663C3BQ91755870-E0F4FC95-33EC-47FB-BA2E-6579765BD6C6Q92876538-3538573E-7B17-4AD8-98B6-BD57624887D8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Shereen Elazzazy
@ast
Shereen Elazzazy
@en
Shereen Elazzazy
@es
Shereen Elazzazy
@nl
Shereen Elazzazy
@sl
type
label
Shereen Elazzazy
@ast
Shereen Elazzazy
@en
Shereen Elazzazy
@es
Shereen Elazzazy
@nl
Shereen Elazzazy
@sl
prefLabel
Shereen Elazzazy
@ast
Shereen Elazzazy
@en
Shereen Elazzazy
@es
Shereen Elazzazy
@nl
Shereen Elazzazy
@sl
P106
P1153
55354827400
P31
P4012
P496
0000-0002-0017-4401